Background: Various proinflammatory cytokines can be detected within the melanoma tumor microenvironment. Interleukin 32 (IL32) is produced by T cells, NK cells and monocytes/macrophages, but also by a subset of melanoma cells. We sought to better understand the biology of IL32 in human melanoma.
features associated with worse prognosis, including angiogenesis, invasion, and metastasis [4] .
However, the role of IL32 in human melanoma cells is less well understood. Initial studies suggested that IL32 expression was related to a more invasive, metastatic phenotype marked by a loss of e-cadherin expression [22] . Others reported that IL32 isoforms alpha and gamma were highly enriched in PD-L1 expressing melanoma specimens [23] .
Herein we report an unbiased analysis of IL32 expression in melanoma using RNA sequencing data from: [1] a large in-house panel of melanoma cell lines and [2] tumor tissues from The Cancer Genome Atlas (TCGA) dataset. IL32 expression correlated with a dedifferentiated phenotype which has been characterized by resistance to targeted therapies, escape from immune recognition, and a high AXL/low MITF genetic signature [24] [25] [26] [27] . Expression of IL32 in human melanoma can be transcriptionally regulated in the context of a proinflammatory tumor microenvironment with either induced or constitutive IL32 expression strongly, but not invariably, correlating with a dedifferentiated genetic signature.
Methods

Cell culture
The human melanoma cell lines were established from patient biopsies. These cells were grown in RPMI 1640 media supplemented with 10% FBS, 1% l-glutamine and 1% penicillin/streptomycin/actinomycin D (Life Technologies, Grand Island, NY). Melanoma cell lines were treated with 1000 IU/mL TNFα and 100 IU/mL IFNγ (PeproTech US, Rocky Hill, NJ) for the indicated time points. M397 was cultured with recombinant 100 ng/ mL IL32α, -β, or -γ (R&D Systems, Minneapolis, MN) for 7 days, with fresh IL32 being added every 2-3 days. Cells were counted using Trypan blue. Jurkat T lymphocytes were cultured in RPMI 1640 supplemented with 10% FBS.
Gene expression analysis
Gene expression FPKM values for the melanoma cell line panel was obtained from the Gene Expression Omnibus (GEO) accession number GSE80829. The hallmark geneset for NF-κB and TNFα signaling (TNFA_SIGNAL-ING_VIA_NFKB) was downloaded from the Molecular Signatures Database (MSigDB). Gene set enrichment analysis of the full ranked list of IL32 correlations was performed using the pre-ranked tool and the GO Biological Process Ontology gene sets from MSigDB v6.1. Gene expression FPKM values of skin cutaneous melanoma tumor biopsies from The Cancer Genome Atlas (TCGA SKCM) was downloaded from the Genomic Data Commons (portal.gdc.cancer.gov). For all analyses, FPKM values were log2 transformed with an offset of 1. Calculation of the enrichment overlap of the top 100 correlated genes with IL32 was performed using the MSigDB investigate gene sets tool (software.broadinstitute.org/gsea/ msigdb/annotate.jsp) and the hallmark gene sets.
Retroviral vectors
IL32 isoforms were cloned into an MSCV retroviral vector with a T2A-GFP using the HiFi DNA Assembly Cloning Kit (NEB, Ipswich, MA). The retroviral vector was kindly provided by A. Ribas. Retroviruses were produced using GP2-293 cells (Clontech, Mountain View, CA) and human melanoma cells were transduced with IL32 expressing retroviral vectors with 4ug/mL Polybrene. GFP positive cells were sorted 48 h after transduction. Cells maintained approximately 95% GFP positivity over the course of the experiment. IL32 expression was confirmed by real time PCR and Western blot.
Real time PCR
RNA was extracted using PureLink RNA Mini Kit (ThermoFisher, Waltham, MA) and cDNA was synthesized using the High-Capacity RNA-to-cDNA kit (ThermoFisher, Waltham, MA). Real time PCRs were performed using the Applied Biosystems 7500 using the following primers designed using NCBI Primer-BLAST. GAPDH was used a housekeeping gene.
IL32 Primers: IL32a Fwd: 5′-GAG GCA ACA GAT CCC CTG TC-3′. IL32a Rev: 5′-GGC TCC GTA GGA CTT GTC AC-3′. IL32b Fwd: 5′-TCT CTC GGC TGA GTA TTT GTGC-3′.  IL32b Rev: 5′-ATG ACC CAG CTC CAC TGA GA-3′.  IL32 g Fwd: 5′-TAC TTC TGC TCA GGG GTT GG-3′.  IL32 g Rev: 5′-TGG GTG CTG CTC CTC ATA AT-3′.  Differentiation gene set:  NGFR Fwd: 5′-TCA TCC CTG TCT ATT GCT CCA-3′.  NGFR Rev: 5′-TGT TCT GCT TGC AGC TGT TC-3′.  MLANA Fwd: 5′-GCT CAT CGG CTG TTG GTA TT-3′.  MLANA Rev: 3′-TTC TTG TGG GCA TCT TCT TG-5′. MITF Fwd: 5′-ATC AGC AAC TCC TGT CCA GC-3′. MITF Rev: 5′-GCC AGT GCT CTT GCT TCA GA-3′. AXL Fwd: 5′-ACC TAC TCT GGC TCC AGG ATG-3′. AXL Rev: 5′-CGC AGG AGA AAG AGG ATG TC-3′. GAPDH Fwd: 5′-TGC ACC ACC AAC TGC TTA GC-3′. GAPDH Rev: 5′-GGC ATG GAC TGT GGT CAT GAG-3′.
5′ rapid amplification of cDNA ends (RACE)
To determine the transcriptional start site of IL32, 5′ RACE was performed according the manufacturer's directions for the SMARTer RACE 5′/3′ kit (Takara, Mountain View, CA). Briefly, RNA was isolated from the IL32 expressing cell line, M318, using NucleoSpin RNA II kits (Takara, Mountain View, CA). First strand cDNA synthesis was done according the manufacturer's directions. The 5′ RACE reaction using the following gene specific primer and a universal primer (Universal Primer Short, UPM, Takara) using 25 cycles of 94° for 30 s, 68° for 30 s, and 72° for 3 min. RACE products were run on an agarose gel and purified using the NucleoSpin Gel and PCR Clean-Up kit (Takara, Mountain View, CA). RACE products were cloned into the pRACE vector using the In-Fusion HD Cloning kit (Takara, Mountain View, CA) and sequenced using the M13F and M13R sequencing primers.
Luciferase constructs
The promoter region of IL32 were pcr'd from the Human BAC clone RP11 (RPC1-11 clone 473M20) using Pfusion DNA polymerase (NEB, Ipswich, MA). Promoter region greater than 3 kb were cloned into pGL3 using HiFi DNA Assembly Cloning Kit (NEB, Ipswich, MA). The promoter regions were derived using the following primers. − 10.5 kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA GCC CGC AGG GAA GAA GGT GAG AGATG-3′.
− 7.5 kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA GCC CCT CTT TAG CGG TGA GTG GGG-3′.
− 5.5 kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA GCC CCA GTA GCT GGC TGT TTC GTG-3′. − 2.5 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTA GAA AGT AGA TGA GGC CAG-3′.
− 2 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTA AAA CAG GGT ACA TAC AGT CTG -3′. − 1.5 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTG GAG TGC AGT GGC ACC AT-3′. − 1.0 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTG TTT GGC CCC AGG AAA CC-3′.
− 0.5 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTC CCC AGC CAG CTG TCC CG-3′. − 2.5 kb to − 0.5 kb Rev: 5′-CTC GAG CTC GAG TGG CGG CCA AAA GTT CAA GGAGC-3′.
− 10.5 kb to − 3 kb Rev: 5′-GAA TGC CAA GCT TAC TTA GAT CGC ATG GCG GCC AAA AGT TCA AG-3′.
Promoter regions were cloned into the SmaI/XhoI (less than − 3.0 kb) or HindIII (greater than − 3.0 kb) sites of pGL3 Luciferase reporter vector (Promega, Madison, WI). Promoter constructs were confirmed by Sanger sequencing. Promoter constructs were transfected into 1.8-2 × 10 4 cells human melanoma cells in equal molar concentrations using Lipofectamine LTX with PLUS Reagent (ThermoFisher, Waltham, MA). pGL4.74 (hRluc/TK, Promega, Madison, WI) was used for transfection normalization. Firefly and Renilla luciferase expression was assessed 48 h after transfection using the Dual-Glo Luciferase Assay system (Promega, Madison, WI). Cells were treated with 1000 IU/mL TNFα and 100 IU/mL IFNγ (PeproTech US, Rocky Hill, NJ) 24 h prior to assessing luciferase activity. All values were normalized to the pGL3 empty vector control.
Myeloid cell polarization
PBMCs were collected using a ficoll gradient (Ficoll-Paque Plus, GE Healthcare) and monocytes were isolated by a CD14 positive selection (Miltenyi, Bergisch Gladbach, Germany). Monocytes were split into five experimental groups: (1) Negative Control (no cytokines), (2) GM-CSF (Sanofi) + IL-4 (Cell Genix) at 1000 U/ml, 3) Recombinant IL32α (R&D Systems) at 100 ng/ml, 4) Recombinant IL32β (R&D Systems) at 100 ng/ml, 5) Recombinant IL32γ (R&D Systems) at 100 ng/ml, and cultured using Cell Genix Media to yield immature DCs at day 5. Immature DC were harvested and surface stained for flow cytometry analysis. Cell surface markers were observed on the double positive, HLA-DR and CD86 population of cells. 
Statistical analyses
Gene expression bar graphs are shown as mean and standard differentiation. Gene expression was normalized to GAPDH and expressed as Delta Ct values. Comparison between the reference control (untreated M397, M398, and M249) was performed with one-way analysis of variance (ANOVA, 95% CI) with a Dunnetts' multiple comparisons test. All calculations were done using Prism software. p-values less than 0.05 were considered statistically significant. For luciferase activity, data was normalized to Renilla luciferase expression and fold changes were calculated against the pGL3 empty control vector. Error bars represent standard deviation.
Results
IL32 expression in human melanoma
We examined RNA sequencing data from a panel of 53 established human melanoma cell lines derived from resected metastatic deposits [25, 26] . Across this dataset, IL32 expression was detectable in a majority of the melanoma cell lines (Fig. 1a) . IL32 expression in a subset of melanoma cell lines was confirmed by real time PCR (data not shown). Immunohistochemical staining of IL32 in melanoma tissues, pulled from The Human Protein Atlas, indicates a range of expression within tumor samples (Additional file 1: Figure S1A ) [28, 29] . However, it is notable that IL32 levels in melanoma are low relative to other tumor cell lines represented in the NCI-60 Cancer Cell Line database or the Cancer Cell Line Encyclopedia (Additional file 1: Figures S1B, C, respectively) [30, 31] .
IL32 expression in human melanoma cell lines and tissues correlates with a dedifferentiated gene signature
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As a confirmatory step, we performed Gene Set Enrichment Analysis on the full ranked list of IL32 expression correlations. Supportive of our earlier findings, the top gene sets highly enriched for IL32 anti-correlation include pigmentation and metabolic gene sets, and the top most highly enriched for IL32 expression include NF-κB and immune related gene sets (Tables 1, 2 ). Together, this suggests that IL32 is among several hundred melanoma genes whose expression is affected by exposure to these proinflammatory cytokines.
TNFα and IFNγ induced IL32 expression in general synchrony with dedifferentiation in melanoma cell lines
To evaluate if IL32 is induced with inflammatory signaling, three non-IL32-producing melanoma cell lines (M397, M398, M249) were exposed to TNFα or IFNγ for 72 h (Fig. 2) . We selected these three melanoma cell (Fig. 3a) . For reference, we also evaluated IL32 transcript levels in the Jurkat T cell line, a recognized high IL32 expressing leukemia cell line. In general, with the exception of M318, the γ isoform is the most abundant and when induced by cytokine stimulation has significantly higher and more prolonged induction (Figs. 2, 3a, b) .
To test the parallel impact of IL32 induction with TNFα or IFNγ treatment on differentiation, we also evaluated expression of melanocytic markers MITF and MLANA, neural crest marker NGFR and the receptor tyrosine kinase AXL. A large and growing body of literature has shown the expression of AXL strongly inversely correlated with the expression of MITF, with a high AXL/ MITF ratio associated with therapy resistance [24, 25] . At baseline, these three melanoma cell lines exhibited a low AXL/high MITF differentiated genetic signature. In two of three cell lines (M397 and M398) we observed inversion of the AXL/MITF ratio towards a dedifferentiated genotype in parallel with induction of IL32. However, one of three cell lines (M249) did not dedifferentiate in response to TNFα or IFNγ, despite induction of IL32. The lack of correlation between IL32 induction and inverted AXL/MITF ratio in M249 suggests that one event is not invariably accompanied by the other. Furthermore, enforced expression of recombinant IL32α, -β, or -γ in M397 did not impact expression of melanoma differentiation genes MITF, AXL, NGFR or MLANA, strongly suggesting that IL32 is not a causal or upstream event in the melanoma dedifferentiation process (Additional file 2: Figure S2 ). 
Proinflammatory cytokines TNFα and IFNγ induce IL32 promoter activity in melanoma cell lines
We characterized the transcriptional regulation of IL32 in human melanoma, both in constitutive and cytokineinduced cells. CHIP-seq analysis of active enhancer and promoter elements, as defined by H3K4Me1, H3K27Ac, H3K3Me3 marks [34] [35] [36] [37] in HUVEC and K562, cell lines known to express IL32, indicate the presence of regulatory elements 5′ relative to the IL32 translational start site (ATG) (Fig. 4a , ENCODE data set; University of California, Santa Cruz (UCSC) genome browser). Using 5′ RACE we determined the location of the transcription start site (TSS) in the IL32 positive cell line M318; two TSS were identified at − 464 bp and − 175 bp (chr16: 3,115,349 and chr16: 3,115,638) relative to the ATG (Fig. 4b) . The Eukaryotic Promoter Database (EPD; http://epd.vital .it.ch) identified two putative IL32 promoters EPD NK4_1 and EPD IL32_1, which are − 558bps and − 221bps relative to the ATG (see "Discussion" Fig. 4b ). Based on this information, we cloned various lengths of the IL32 5′ upstream genomic region (− 10.5, − 7.5, − 5.5, − 2.5, − 2, − 1.5, − 1, − 0.5) into a luciferase reporter construct; these constructs encompassed the putative EPD promoters, both identified TSS sites, and the upstream (5′) ENCODE histone marks. These constructs were transiently transfected into IL32 negative (M249, M397) and IL32 positive (M318) cell lines (Fig. 4d) . Strong promoter activity was noted in the IL32 positive but not the negative cell lines, with the highest level in the − 10.5 and − 1.5 constructs. When both IL32 negative cell lines were exposed to TNFα or IFNγ for 24 h, there was a significant induction of promoter activity. TNFα consistently induced stronger IL32 promoter activity than IFNγ. M249, which cannot be dedifferentiated with TNFα or IFNγ, also showed strong IL32 promoter induction consistent with IL32 transcript expression. The promoter construct profiles were similar in both constitutive and induced settings.
IL32 in the melanoma microenvironment is associated with immune infiltration and melanoma dedifferentiation
Given the impact of TNFα and IFNγ on IL32 expression in melanoma cell lines, we investigated the expression of IL32 in the chemokine-rich melanoma tumor microenvironment using RNA sequencing data from Post-transduction cells were treated for 24 h with 1000 U/mL TNFα and 100 U/mL IFNγ. Luciferase activity was assessed using Dual-Glo according to the manufactures directions. Data was normalized to Renilla luciferase expression and fold changes were calculated against the pGL3 empty control vector. Luciferase assays were performed in triplicate and plotted data is a representative experiment of three independent experiments Page 9 of 13 Paz et al. J Transl Med (2019) 17:113 tumor biopsies as part of The Cancer Genome Atlas (TCGA) dataset. We observed strong Pearson correlation coefficients between IL32 expression, found within the melanoma tumor and the surrounding microenvironment, and genes related to immune cell infiltration, such as CD3E (0.94), CD8A (0.89), IFNγ (0.75), and GZMB (0.86) (Additional file 3: Figure S3 ). Additionally, we observed a strong correlation between IL32 expression and several checkpoint receptors and ligands, such as PD-1 (0.87), PD-L1 (0.69), Tim-3 (0.82), Lag3 (0.85), and TIGIT (0.86) (Additional file 4: Figure S4 ). We also observed correlations between IL32 and genes related to other immune subsets, including myeloid cells ( ). In light of the impact of a proinflammatory microenvironment on melanoma differentiation, as well as the association between IL32 and dedifferentiation in melanoma cell lines, we investigated if this phenomenon was also present in the TCGA dataset. We observed a correlation between IL32 expression in melanoma tumor biopsies with a high AXL/low MITF drug-resistant signature, consistent with data from melanoma cell lines (Additional file 3: Figure S3 ). However, IL32 did not inversely correlate with signature melanocyte genes (MLANA, PMEL, TYR ) as we observed in the cell line data (data not shown). Additionally, IL32 expression did not correlate with genes associated with disease progression, tumor cell invasion, and migration, such as CD155/PRV and MMP2 (Additional file 4: Figure S4 ).
IL32 isoforms have differential impact on myeloid polarization
IL32 from melanoma cells may influence non-melanoma cells in the tumor microenvironment, such as myeloid cells, which can play both pro-and anti-tumor roles depending on their phenotypic state. We preliminarily assessed of the impact of IL32 on the polarization of myeloid cells. It has previously been reported that IL32γ induces the differentiation of monocytes into phagocytic macrophage-like cells (though they discordantly express CD14 and CD1a) [19] . However, the effect of IL32γ, or other IL32 isoforms (IL32α and IL32β), on myeloid cell polarization is not well understood. We observed that monocytes cultured with either IL32β or IL32γ express both CD68 and CD80, markers associated with M1 proinflammatory macrophages thought to play an antitumor role (Additional file 5: Figure S5 ). In contrast, exposure to IL-32α resulted in a CD68+ but CD80− population. Likewise, IL32β and IL32γ, but not IL32α, resulted in higher CD14 and CD1b expression.
Discussion
Human melanomas produce a number of cytokines generally associated with the immune system [38] . In an analysis of the RNA transcripts from 53 established melanoma lines, a significant proportion express IL32 isoforms. Thus, we evaluated the biology underlying IL32 expression in the context of melanoma both in cell lines and in melanoma tumor samples.
IL32 is found on human chromosome 16p13.3, is expressed in at least 6 splice variants (α, β, γ, δ, ε, ζ) and was originally isolated from activated natural killer and T cells [16] . Which isoforms are secreted as opposed to acting intracellularly is still unresolved and hampered by an as of yet unidentified cell surface receptor [39, 40] . The γ isoform is the only isoform that has a leader sequence, is composed of all exons, is believed to be secreted, and believed to be the most biologically active [41] . A rodent IL32 homologue does not exist-raising the obvious question as to whether or not this gene product is dispensable or redundant-but human recombinant and transgenic IL32 appears to be biologically active in mice [12, [42] [43] [44] . Despite these gaps in our knowledge, much of the published literature on the biology of IL32 comes from experiments utilizing commercially available recombinant protein, generally the α, β, and γ isoforms [1] .
Several themes emerge regarding IL32 biology: (a) IL32 can modulate the production of various cytokines including IL1β [45] , TNFα [46] , IL6 [47] , IL8 [8] , and may activate cells of the immune system [15, 19] ; (b) IL32 expression can be induced by various viruses and microbes [2, 20, 42, [48] [49] [50] [51] and may play a role in antiviral immunity [52] ; (c) IL32 may have direct effects on various cancer cells in vitro; [8, 9, 22, 47, 53, 54] ; (d) IL32 may play a role in tumor immunity [4, 7, 12, 14, 44] ; [41] ; and (e) IL32 has been associated with various inflammatory diseases [43, 45] , such as ulcerative colitis and rheumatoid arthritis [55] . It is also curious that, largely from immunohistochemistry studies, IL32 is expressed by a broad range of epithelial and in hematopoietic malignancies and is generally correlated with aggressive biology, although no unifying mechanism has been identified.
In comparing IL32 expressing and non-expressing melanoma cell lines, we observed that IL32 expression in melanoma cell lines correlates with a high AXL/ low MITF ratio, a genetic signature which has been reported to be associated with a treatment-resistant, dedifferentiation "invasive" phenotype. This dedifferentiation phenotype results in reduced expression of melanocyticlineage antigens, which may also provide a mechanism for immune evasion [32] . Melanomas, which progress on MAPK inhibitor therapies, acquire this genetic signature of reduced MITF and RTK upregulation [25] . MITF controls the expression of a broad range of genes in melanocyte-lineage cells that govern differentiation, migration, and proliferation [56] [57] [58] . The low MITF signature is regulated by receptor tyrosine kinases, including AXL [59] .
The plasticity of these neural crest-derived cutaneous malignancies is underscored by the ability of an inflammatory signal-TNFα or IFNγ, for example-to effect a differentiated to dedifferentiated conversion in melanoma cell lines with only a 72 h in vitro exposure, a phenomenon that reverses when the cytokine is removed from culture [26] . We found that TNFα and IFNγ, which promote a dedifferentiated melanoma phenotype, also induce IL32 expression in non-IL32 expressing melanoma cell lines by impacting activity at the promoter level.
Palstra et al. recently reported that the DNA element encompassing rs4349147 is a strong long distance enhancer essential for the expression of IL32 in CD4 T cells located 10 kb 3′ of the IL32 promoter [52] . Jurkat cells are heterozygous for the rs4349147-A and rs4349147-G alleles. The A allele increases the expression of IL32α, generally viewed as anti-inflammatory, whereas the G allele promoted the expression of the proinflammatory IL32γ and IL32β isoforms. These proinflammatory isoforms enhanced lymphocyte activation and susceptibility to HIV infection. This report provides considerable insight into various observations on the biology of IL32 isoforms. Two putative IL32 promoters have been identified using the Eukaryotic Promoter Database (http://epd. vital -it.ch), which are depicted in Fig. 4 . These two promoters, at least in Jurkat cells, designated EPD NK4_1 and EPD IL32_1, are thought to support the transcription of IL32γ and IL32α/β, respectively. Our IL32 promoter constructs encompass both the identified EPD NK4_1 and EPD IL32_1 putative promoter regions and extend 10.5 kb 5′ to the ATG. The luciferase activity driven by these constructs would then necessarily reflect constitutive and induced gene expression of all three isoforms, as well as the putative cis-acting elements residing within this 5′ upstream region. Palstra et al. performed formaldehyde-assisted isolation of regulatory elements (FAIRE) assays in Jurkat and a melanoma cell line (G361), which demonstrated significant increase in DNA accessibility in the region surrounding rs4349147 in the former but not the latter cell line [52] . We therefore conjecture that this long-range enhancer may not play a role in melanoma IL32 transcription. In another IL32 promoter study using Akt-activated endothelial cell line constructs extending 2.5 kb 5′ to the ATG [60] ; the difference in cell lines and activation signals precludes any meaningful comparison.
Given the impact of proinflammatory cytokines on IL32 expression, we investigated the IL32 expression in immunologically rich melanoma tumors using RNA sequencing data available in the TCGA dataset. IL32 expression was highly correlated with a T cell dominant immune signature in these tumors, probably a result of immune cell IL32 production. We also observed a correlation between IL32 expression, derived from tumor cells and the surrounding microenvironment, and a high AXL/ low MITF gene signature, as in the melanoma cell lines. However, we interpret this result cautiously because, unlike in the melanoma cell line dataset, IL32 expression in the melanoma tumor microenvironment did not inversely correlate with pigmentation or melanoma differentiation genes such as MLANA, TYR or PMEL. Thus, the high AXL/low MITF signature may be a result of increased IL32 expression by infiltrating immune cells, rather than IL32 expressing dedifferentiated melanoma cells in the tumor microenvironment.
There is substantial evidence that IL32 induces dedifferentiation of human monocytes towards a macrophagelike phonotype with dendritic cell-like aspects. IL32 exposed monocytes altered their morphology within 3 days (flattening with extensive pseudopodia), which was accompanied by increased expression of CD1 and CD14 [19] . These macrophage-like cells exhibited active phagocytic properties and were also induced to express TNFα, IL-1β and IL6. Our preliminary in vitro studies indicated that IL32, in an IL32β and IL32γ isoform specific manner, can modulate the polarization of myeloid cells toward an M1-like macrophage phenotype with costimulatory molecule expression, lending additional support for its impact in the tumor microenvironment. It is plausible, then, that IL32 is expanded within the microenvironment as a byproduct of the feedback loop between the antitumor inflammatory response (marked by TNFα and IFNγ) and dedifferentiation of melanoma [23] .
Conclusions
In summary, this study shows that a significant percentage of cell lines derived from metastatic melanoma express IL32. IL32 expression, which correlates with a dedifferentiated "invasive" genetic signature, can be induced by inflammatory molecules TNFα and IFNγ that modulate IL32 transcriptional activity at the promoter level. IL32 expression by dedifferentiated tumor cells may contribute to a proinflammatory tumor microenvironment.
The remarkable advances in melanoma immunotherapy occasioned by the development of CTLA-4
